Pharma Technology – NHS reforms

Pharma Technology - The Challenges Facing Decision Makers

Laboratories within the pharma industry are placed under a great deal of pressure to cut costs, provide tangible results and prove to healthcare organisations that their data and information is stored in a safe and easy to access environment. They must constantly be looking for ways to optimise the business value of their data, to accelerate innovation, reduce risk and improve operational efficiencies.

Subscribe to our newsletter now to stay on top of the latest development in Pharma technology!

A report by Kalorama Information, the healthcare market research publisher, called Laboratory Information Systems Markets has discussed future developments of this area, focussing on pharma technology developments to aid future progress. They predict that labs will rely more and more on sophisticated, easy to use and fast information systems to process and store high volume and complex data.

They predict that using automation will drastically reduce testing costs, by reducing reliance on expensive labour, optimising efficiency by lessening the numbers of hands on procedures carried out. This means that laboratories are increasingly finding that they need to move to more sophisticated data collection methods in order to cut costs, increase efficiencies and report test results in real time. It is becoming increasingly necessary to embrace pharma technology in order to remain competitive.

Hospitals are embracing technology, and laboratories will need to be able to interface with these systems in order to remain a viable partner in the future. Efficiencies of real-time data integration, reporting and analytics are essential in keeping costs low and continually improving and streamlining patients’ treatment. This of course means that LIS will need to be able to work with multiple systems, including less technical and complex set ups from smaller labs and clinics. The more systems that embrace technology, the easier it will be to collate a full picture of a patient’s history and diagnosis.

Additionally, as both pathology and molecular biology are becoming increasingly automated and digitised as products become more economically viable due to rising volumes, this is helping to fuel the growth of LIS. Although there is a long way to go before there is complete and widespread use of LIS, one thing that is clear is that pharma technology will only move forwards in the years to come.

To read more about this and other pharma technology trends throughout the industry, visit Pharma IQ where you can download whitepapers and webinars on a range of essential topics.